Abstract

Daridorexant, a double orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA), has been recently introduced in the market for the treatment of insomnia. DORAs are a new form of sleep drugs that can be used instead of standard positive allosteric gamma-amino butyric acid (GABA)-A receptor modulators. Daridorexant blocks the effects of the wake promoting orexin (also known as hypocretin) neuropeptides by binding specifically to both orexin receptors. This approach avoids the extensive inhibition of neuronal circuits that positive allosteric GABA-A receptor modulators cause, as well as the related adverse effects. In this reviewdetailed Pharmacology of Daridorexant including its mechanism of action, Pharmacodynamics, and Pharmacokinetics have been compiled.

• 1.   Dauvilliers, Y. et al. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder. Ann. Neurol.87, 347–356 (2020).
• 2.   Roch, C., Bergamini, G., Steiner, M. A. & Clozel, M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl).238, 2693–2708 (2021).
• 3.   Muehlan, C., Vaillant, C., Zenklusen, I., Kraehenbuehl, S. & Dingemanse, J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin. Drug Metab. Toxicol.16, 1063– 1078 (2020).
• 4.   Atkin, T., Comai, S. & Gobbi, G. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacol. Rev.70, 197–245 (2018).
• 5.   Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N. & Heald, J. L. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J. Clin. Sleep Med.13, 307–349 (2017).
• 6.   Dolder, C. R. & Nelson, M. H. Hypnosedativeinduced complex behaviours : incidence, mechanisms and management. CNS Drugs22, 1021– 1036 (2008).
• 7.   Frey, D. J., Ortega, J. D., Wiseman, C., Farley, C. T. & Wright, K. P. Influence of zolpidem and sleep inertia on balance and cognition during nighttime awakening: a randomized placebo-controlled trial. J. Am. Geriatr. Soc.59, 73–81 (2011).
• 8.   Effects of daytime administration of zolpidem and triazolam on performance - PubMed. https:// pubmed.ncbi.nlm.nih.gov/8834935/.
• 9.   DN, N., SR, P.-P., DW, S., K, B. & JM, M. Pharmacotherapy of Insomnia. J. Cent. Nerv. Syst. Dis.10, 1468–1470 (2018).
• 10.   Brisbare-Roch, C. et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med.13, 150–155 (2007).
• 11.   Scammel, T. E. & Winrow, C. J. Orexin Receptors: Pharmacology and Therapeutic Opportunities. http://dx.doi.org/10.1146/annurevpharmtox-010510-10052851, 243–266 (2011).
• 12.   Muehlan, C. et al. Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study. Clin. Pharmacol. Ther.104, 1022–1029 (2018).
• 13.   https://link.springer.com/article/10.1007/s40265- 022-01699-y(Accessed on 26 June2022).
• 14.   h t t ps :/ / w w w . id or s i a .c o m / m ed i a/ n ew sdetails?newsId=2665386(Accessed on 26 June 2022)
• 15.   https://www.accessdata.fda.gov/drugsatfda_ docs/label/2022/214985s000lbl.pdf (Accessed on 26 June 2022)
• 16.   Herring, W. J., Roth, T., Krystal, A. D. & Michelson, D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J. Sleep Res.28, (2019).
• 17.   Janto, K., Prichard, J. R. & Pusalavidyasagar, S. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics. J. Clin. Sleep Med.14, 1399 (2018).
• 18.   Treiber, A. et al. The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. J. Pharmacol. Exp. Ther.362, 489–503 (2017).
• 19.   Muehlan, C., Brooks, S., Zuiker, R., van Gerven, J. & Dingemanse, J. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeateddose morning and evening administration. Eur. Neuropsychopharmacol.29, 847–857 (2019).
• 20.   Muehlan, C. et al. Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry. Curr. Drug Metab.20, 254–265 (2019).
• 21.   Berger, B., Muehlan, C., Klein, G. & Dingemanse, J. Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment. Clin. Transl. Sci.14, 2132–2138 (2021).
• 22.   Berger, B. et al. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clin. Pharmacokinet.60, 1349–1360 (2021).
• 23.   Gehin, M., Wierdak, J., Sabattini, G., Sidharta, P. N. & Dingemanse, J. Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist. Br. J. Clin. Pharmacol.88, 810–819 (2022).
• 24.   Berger, B., Kornberger, R. & Dingemanse, J. Pharmacokinetic and Pharmacodynamic interactions between Daridorexant, a dual orexin receptor antagonist, and Citalopram in healthy subjects. Eur. Neuropsychopharmacol.51, 90–104 (2021).
• 25.   Zenklusen, I., Muehlan, C., Ulc, I., Liška, J. & Dingemanse, J. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin. Clin. Exp. Pharmacol. Physiol.47, 1843–1849 (2020).
• 26.   Roch, C., Bergamini, G., Steiner, M. A. & Clozel, M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl).238, 2693–2708 (2021).
• 27.   Jacobson, L. H., Hoyer, D. & de Lecea, L. Hypocretins (orexins): The ultimate translational neuropeptides. J. Intern. Med.291, 533–556 (2022).

Data Sharing Statement

Funding